To Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

NCT03291418 PHASE1, PHASE2 COMPLETED

A Double-Blind, Controlled Study to Compare the Gastrointestinal Safety of a 14-Day Oral Dosing Regimen of ATB-346 to Sodium Naproxen in Healthy Subjects

Details

Lead sponsor	Antibe Therapeutics Inc.
Phase	PHASE1, PHASE2
Status	COMPLETED
Enrolment	258
Start date	Fri Sep 08 2017 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Apr 30 2018 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

• Gastric Ulcer

Interventions

• ATB-346 OR Placebo
• Naproxen sodium

Countries

Canada